14.02.2008 16:00:00
|
TRADE NEWS: Agilent Technologies Provides Oligo Libraries for Hannon Lab to Develop New Generation of Gene-Silencing Libraries
Agilent Technologies Inc. (NYSE:A) today announced an agreement to
provide the Hannon laboratory at Cold Spring Harbor Laboratory (CSHL)
with oligonucleotide libraries to further develop the widely used small
hairpin RNA interference (shRNA) libraries.
Howard Hughes Medical Institute investigators Gregory Hannon, Ph.D., at
CSHL, and Stephen Elledge, Ph.D., the Gregor Mendel professor of
Genetics at Harvard Medical School, pioneered the generation of
plasmid-based shRNA libraries. These libraries contain constructs
against all identified genes in the human and mouse genomes with the
unique ability to silence targeted genes very specifically and
effectively over long time periods. The earlier collaborative work was
published in Nature Methods 1, 241-248 (2004) and Nature
Genetics 37, 1281-1288 (2005).
"Agilent has significantly improved its
programmable in-situ oligonucleotide synthesis technology since the original
publication, and we’ve developed the
capability to synthesize as many as 55,000 oligonucleotides per library,
and also make them as long as 200 bases,” said
Emily LeProust, Ph.D., R&D chemistry manager, Genomics for Agilent. "This
means that we can provide Dr. Hannon with high quality starting material
in a massively parallel fashion and at a cost significantly lower than
current oligonucleotide synthesis technology.” "The 100 base-pair barrier has been broken,
and researchers no longer need to combine individually synthesized
oligos from microplates into a single tube,”
she added.
Agilent says that it is producing at a very low error rate (one out of
250 bases or better), and is delivering quantities from 0.2 fmol to tens
of fmols per oligo. The flexible synthesis platform permits rapid
prototyping of an oligo mixture prior to scale-up for larger studies.
The ability to synthesize long oligos of high quality enables novel
approaches to the study of biological problems and systems. Agilent
oligo libraries are available to selected users under an early access
program.
Agilent is a leading worldwide provider of microarray-based genomics
solutions. It provides research tools that enable scientists to study a
wide range of applications including gene expression, alternative
splicing, chromosomal aberrations and gene copy number (aCGH),
protein/DNA interactions (ChIP on Chip) and DNA methylation. For further
details about Agilent’s microarray solutions,
visit www.opengenomics.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE:A) is the world’s
premier measurement company and a technology leader in communications,
electronics, life sciences and chemical analysis. The company’s
19,000 employees serve customers in more than 110 countries. Agilent had
net revenue of $5.4 billion in fiscal year 2007. Information about
Agilent is available on the Web at www.agilent.com.
Further technology, corporate citizenship and executive news is
available on the Agilent news site at www.agilent.com/go/news.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Agilent Technologies Inc.mehr Nachrichten
Analysen zu Agilent Technologies Inc.mehr Analysen
Aktien in diesem Artikel
Agilent Technologies Inc. | 128,78 | -0,16% |
Indizes in diesem Artikel
S&P 500 | 6 032,38 | 0,56% |